Studies of CB1 antagonists more consistently showed improvement of motor symptoms.73–77 Blockade of CB1R with rimonabant or other antagonists reduced akinesia and motor impairment in experimental models of PD,73,75,77,78 although a few other studies showed conflicting results.9,66 Moreover, rimonabant was more effective when used at low doses,75,77 and in very advanced phases of the disease characterized by extreme nigral damage.73 These effects appear to involve nondopaminergic mechanisms, including enhanced striatal glutamate release.9,73,75. Here, CNR1 is linked to Parkinson disease.